Garrett M. Draper
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Garrett M. Draper has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- David A. Largaespada
Department of Pediatrics, University of Minnesota, Minneapolis, MN 55455, USA
25 shared publications - Kyle B. Williams
Department of Pediatrics, University of Minnesota, Minneapolis, MN 55455, USA
24 shared publications - Alex T. Larsson
Department of Pediatrics, University of Minnesota, Minneapolis, MN 55455, USA
23 shared publications Bryant J. Keller
20 shared publications- Christopher L. Moertel
Department of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota
20 shared publications - Minu M. Bhunia
Department of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota
20 shared publications
Latest Publications
- Open Access
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 8 from Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors
Supplementary Figure 8 shows the pathway enrichment in transcriptome data for MPNST cells treated with selumetinib, rigosertib, or the combination.
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 8 from Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors
Supplementary Figure 8 shows the pathway enrichment in transcriptome data for MPNST cells treated with selumetinib, rigosertib, or the combination.
- Open Access
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors
Supplementary Table 4 shows the median survival (as determined by Kaplan Meier analysis) for a genetically engineered mouse model of peripheral nerve sheath tumors which have been treated with therapeutic agents from this study.
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors
Supplementary Table 4 shows the median survival (as determined by Kaplan Meier analysis) for a genetically engineered mouse model of peripheral nerve sheath tumors which have been treated with therapeutic agents from this study.
- Open Access
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 7 from Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors
Supplementary Figure 7 shows the pathway enrichment in transcriptome data for MPNST cells treated with selumetinib, digoxin, or the combination.
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 7 from Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors
Supplementary Figure 7 shows the pathway enrichment in transcriptome data for MPNST cells treated with selumetinib, digoxin, or the combination.
- Open Access
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors
Supplementary Table 2 lists the small molecule libraries screen in this work.
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors
Supplementary Table 2 lists the small molecule libraries screen in this work.
- Open Access
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors
Supplementary Figure 4 shows the expanded gating strategy used for cell cycle analysis of drug treated MPNST cell lines.
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors
Supplementary Figure 4 shows the expanded gating strategy used for cell cycle analysis of drug treated MPNST cell lines.
- Open Access
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors
Supplementary Figure 5 shows the drug dose response curves of NF1 -/- vs NF1 ± cells treated with the drugs of interest in this study.
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors
Supplementary Figure 5 shows the drug dose response curves of NF1 -/- vs NF1 ± cells treated with the drugs of interest in this study.
- Open Access
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors
Supplementary Table 3 shows the combination index determination results of small molecules used in this study when combined with a MEK inhibitor.
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors
Supplementary Table 3 shows the combination index determination results of small molecules used in this study when combined with a MEK inhibitor.
- Open Access
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 12 from Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors
Supplementary Figure 12 shows Kaplan Meier survival analysis and tumor volume measurements of a PDX treated with selumetinib, rigosertib, and the combination.
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 12 from Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors
Supplementary Figure 12 shows Kaplan Meier survival analysis and tumor volume measurements of a PDX treated with selumetinib, rigosertib, and the combination.
- Open Access
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors
Supplementary Figure 6 shows the effects of combination drug therapy on NF1 -/- vs NF1 ± human Schwann cell lines.
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors
Supplementary Figure 6 shows the effects of combination drug therapy on NF1 -/- vs NF1 ± human Schwann cell lines.
- Open Access
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors
Supplementary Figure 2 shows that NF1 deficient human Schwann cell clones have increased RAS-GTP levels.
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors
Supplementary Figure 2 shows that NF1 deficient human Schwann cell clones have increased RAS-GTP levels.